Cambridge Raman Imaging

Cambridge Raman Imaging Limited, founded in March 2018, specializes in developing advanced coherent Raman scattering microscopy technology for the biomedical market. The company primarily serves pharmaceutical companies, research institutions, and healthcare providers. Operating in the high-tech imaging sector, Cambridge Raman Imaging leverages a combination of private and public funding to innovate and commercialize its products. The business model revolves around selling high-resolution imaging solutions and related services, generating revenue through direct sales and long-term service contracts. In 2020, the company expanded its global footprint by establishing a wholly-owned subsidiary, CRI S.r.l, in Italy. This move aims to accelerate the commercialization of its cutting-edge technology. The company's pioneering laser technology, computational imaging, and AI capabilities enable rapid and precise imaging, which is crucial for applications such as drug discovery, therapy assessment, and cellular process analysis. The technology also finds applications in the semiconductor industry for high-speed characterization of bulk semiconductors and layered materials like graphene.

Keywords: coherent Raman scattering, microscopy, pharmaceutical, drug discovery, high-resolution imaging, biomedical, laser technology, AI, semiconductor, CRI S.r.l.